Skip to main content
SpringerLink
Log in

Pathophysiological Role of Leukotrienes in Dermatological Diseases

Potential Therapeutic Implications

  • Review Article
  • Published:
BioDrugs Aims and scope Submit manuscript

Abstract

In vitro and in vivo data have demonstrated that leukotrienes play a key role not only in allergic airway diseases but also in inflammatory reactions of the skin. Antileukotriene drugs, i.e. leukotriene receptor antagonists and synthesis inhibitors, are a new class of anti-inflammatory drugs that have shown clinical efficacy in the management of asthma, allergic rhinitis and inflammatory bowel disease. To address the question of the validity and applicability of published evidence of the use of antileukotriene drugs in dermatological diseases, we reviewed data concerning the pathophysiological effect of leukotrienes in the skin and in skin diseases, and the experience with antileukotriene treatment that has been published.

In vivo and in vitro data suggest that antileukotriene treatment may have efficacy in atopic dermatitis, different types of urticaria or psoriasis and other skin diseases such as bullous skin diseases, collagenoses, Sjogren-Larsson syndrome or Kawasaki disease. Nevertheless, published evidence is very limited and before any conclusions can be drawn, additional basic research needs to be performed with regard to the role of different leukotrienes and leukotriene receptors in skin diseases.

On the basis of these data, randomised and placebo-controlled clinical trials with leukotriene antagonists and synthesis inhibitors should be performed. Moreover, future studies investigating the additive benefit of antileukotriene drugs are warranted, e.g. in combination with antihistamines, corticosteroids or other antiinflammatory drugs.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Table I
Table II
Table III
Table IV
Table V
Table VI
Table VII

Similar content being viewed by others

References

  1. Kellaway CH, Trethewie ER. The liberation of a slow reacting smooth muscle-stimulating substance in anaphylaxis. Q J Exp Physiol 1940; 30: 121–45

    CAS  Google Scholar 

  2. Lewis RA, Austen KF. The biologically active leukotrienes: biosynthesis, metabolism, receptor function and pharmacology. J Clin Invest 1984; 73: 889–97

    Article  PubMed  CAS  Google Scholar 

  3. Devillier P, Baccard N, Advenier C. Leukotrienes, leukotriene receptor antagonists and leukotriene synthesis inhibitors in asthma: an update. Part II: clinical studies with leukotriene receptor antagonists and leukotriene synthesis inhibitors in asthma. Pharmacol Res 1999; 40: 15–29

    Article  PubMed  CAS  Google Scholar 

  4. Devillier P, Baccard N, Advenier C. Leukotrienes, leukotriene receptor antagonists and leukotriene synthesis inhibitors in asthma: an update. Part I: synthesis, receptors and role of leukotrienes in asthma. Pharmacol Res 1999; 40: 3–13

    Article  PubMed  CAS  Google Scholar 

  5. Moqbel R. Leukotriene receptor antagonists in the treatment of asthma: implications for eosinophilic inflammation. Can Respir J 1999; 6: 453–7

    PubMed  CAS  Google Scholar 

  6. Leff JA. Leukotriene modifiers as novel therapeutics in asthma. Clin Exp Allergy 1998; 28: 147–53

    Article  PubMed  CAS  Google Scholar 

  7. McGill KA, Busse WW. Zileuton. Lancet 1996; 348: 519–24

    Article  PubMed  CAS  Google Scholar 

  8. Reichmuth D, Lockey RF. Present and potential therapy for allergic rhinitis. BioDrugs 2000; 14: 371–87

    Article  PubMed  CAS  Google Scholar 

  9. Dahlen SE. Leukotriene receptors. Clin Rev Allergy Immunol 1999; 17: 179–91

    Article  PubMed  CAS  Google Scholar 

  10. Casellas F, Guarner F. Eicosanoids in inflammatory bowel disease: therapeutic implications. Clin Immunother 1996; 6(5): 333–40

    Article  Google Scholar 

  11. Iversen L, Kristensen P, Nissen JB, et al. Purification and characterization of leukotriene A4 hydrolase from human epidermis. FEBS Lett 1995; 358: 316–22

    Article  PubMed  CAS  Google Scholar 

  12. Ford-Hutchinson AW. 5-lipoxygenase activation in psoriasis: a dead issue? Skin Pharmacol 1993; 6: 292–7

    Article  PubMed  CAS  Google Scholar 

  13. Iversen L, Fogh K, Ziboh VA, et al. Leukotriene B4 formation during human neutrophil keratinocyte interactions: evidence for transformation of leukotriene A4 by putative keratinocyte leukotriene A4 hydrolase. J Invest Dermatol 1993; 100: 293–8

    Article  PubMed  CAS  Google Scholar 

  14. Koro O, Furutani K, Hide M, et al. Chemical mediators in atopic dermatitis: involvement of leukotriene B4 released by a type I allergic reaction in the pathogenesis of atopic dermatitis. J Allergy Clin Immunol 1999; 103: 663–70

    Article  PubMed  CAS  Google Scholar 

  15. Larkin S W, Fraser L, Showell HJ, et al. Prolonged microvascular vasodilatation induced by leukotriene B4 in human skin is cyclooxygenase independent. J Pharmacol Exp Ther 1995; 272: 392–8

    PubMed  CAS  Google Scholar 

  16. Rosenbach T, Grabbe J, Moller A, et al. Generation of leukotrienes from normal epidermis and their demonstration in cutaneous disease. Br J Dermatol 1985; 113: 157–67

    Article  PubMed  CAS  Google Scholar 

  17. Paulissen M, Peereboom-Stegeman JH, van de Kerkhof PC. An ultrastructural study of transcutaneous migration of polymorphonuclear leukocytes following application of LTB4. Skin Pharmacol 1990; 3: 236–47

    Article  PubMed  CAS  Google Scholar 

  18. Songzhu A, Goetzl EJ. Lipid mediators of hypersensitivity and inflammation. In: Middleton E, Ellis EF, Yunginger JW, editors. Allergy: principles and practice. St. Louis: Mosby, 1998: 168–82

    Google Scholar 

  19. Kragballe K, Desjarlais L, Voorhees JJ. Leukotrienes B4, C4 and D4 stimulate DNA synthesis in cultured human epidermal keratinocytes. Br J Dermatol 1985; 113: 43–52

    Article  PubMed  CAS  Google Scholar 

  20. Muller A, Michel L, Basset-Seguin N, et al. Characterization of specific leukotriene C4 binding sites on cultured human keratinocytes. Br J Dermatol 1988; 119: 275–80

    Article  PubMed  CAS  Google Scholar 

  21. Reusch MK, Wastek GJ. Human keratinocytes in vitro have receptors for leukotriene B4. Acta Derm Venereol 1989; 69: 429–31

    PubMed  CAS  Google Scholar 

  22. Andoh T, Kuraishi Y. Intradermal leukotriene B4, but not prostaglandin E2, induces itch-associated responses in mice. Eur J Pharmacol 1998; 353: 93–6

    Article  PubMed  CAS  Google Scholar 

  23. MacGlashan DW Jr D, Schleimer RP, Peters SP, et al. Generation of leukotrienes by purified human lung mast cells. J Clin Invest 1982; 70: 747–51

    Article  PubMed  CAS  Google Scholar 

  24. Du JT, Foegh M, Maddox Y, et al. Human peritoneal macrophages synthesize leukotrienes B4 and C4. Biochim Biophys Acta 1983; 753: 159–63

    Article  PubMed  CAS  Google Scholar 

  25. Radeau T, Godard P, Chavis C, et al. Effect of nedocromil sodium on sulfidoleukopeptide leukotrienes-stimulated human alveolar macrophages in asthma. Pulm Pharmacol 1993; 6: 27–31

    Article  PubMed  CAS  Google Scholar 

  26. Fiore S, Serhan CN. Formation of lipoxins and leukotrienes during receptor-mediated interactions of human platelets and recombinant human granulocyte/macrophage colony-stimulating factor-primed neutrophils. J Exp Med 1990; 172: 1451–7

    Article  PubMed  CAS  Google Scholar 

  27. Yokomizo T, Izumi T, Chang K, et al. A G-protein-coupled receptor for leukotriene B4 that mediates chemotaxis. Nature 1997; 387: 620–4

    Article  PubMed  CAS  Google Scholar 

  28. Yokomizo T, Kato K, Terawaki K, et al. A second leukotriene B(4) receptor, BLT2. A new therapeutic target in inflammation and immunological disorders. J Exp Med 2000; 192: 421–32

    Article  PubMed  CAS  Google Scholar 

  29. Michel L, Dubertret L. Leukotriene B4 and platelet-activating factor in human skin. Arch Dermatol Res 1992; 284: S12–7

    Article  PubMed  CAS  Google Scholar 

  30. Camps RDR, Coutts AA, Greaves MW, et al. Responses of human skin to intradermal injection of leukotrienes C4, D4, and B4. Br J Pharmacol 1983; 80: 497–502

    Article  Google Scholar 

  31. Williams TJ, Piper PJ. The action of chemically pure SRS-A on the microcirculation in vitro. Prostaglandins 1980; 19: 779–86

    Article  PubMed  CAS  Google Scholar 

  32. Soter NA, Lewis RA, Corey EJ, et al. Local effects of synthetic leukotrienes (LTC4, LTD4, LTE4, and LTB4) in human skin. J Invest Dermatol 1983; 80: 115–9

    Article  PubMed  CAS  Google Scholar 

  33. Bisgaard H, Lerche A, Kristensen JK. Leukotriene- and histamine-induced increases in vascular permeability and interstitial transport in the skin. J Invest Dermatol 1985; 84: 427–9

    Article  PubMed  CAS  Google Scholar 

  34. Maxwell DL, Atkinson BA, Spur BW, et al. Skin responses to intradermal histamine and leukotrienes C4, D4, and E4 in patients with chronic idiopathic urticaria and in normal subjects. J Allergy Clin Immunol 1990; 86: 759–65

    Article  PubMed  CAS  Google Scholar 

  35. Talbot SF, Atkins PC, Goetzl EJ, et al. Accumulation of leukotriene C4 and histamine in human allergic skin reactions. J Clin Invest 1985; 76: 650–6

    Article  PubMed  CAS  Google Scholar 

  36. Panettieri RA, Tan EM, Ciocca V, et al. Effect of LTD4 on human airway smooth muscle cell proliferation, matrix expression, and contraction in vitro: differential sensitivity to cysteinyl leukotriene receptor antagonists. Am J Respir Cell Mol Biol 1998; 19: 453–61

    PubMed  CAS  Google Scholar 

  37. Yamaya M, Sekizawa K, Yamauchi K, et al. Epithelial modulation of leukotriene-C4-induced human tracheal smooth muscle contraction. Am J Respir Crit Care Med 1995; 151: 892–4

    PubMed  CAS  Google Scholar 

  38. Kane GC, Pollice M, Kim CJ, et al. A controlled trial of the effect of the 5-lipoxygenase inhibitor, zileuton, on lung inflammation produced by segmental antigen challenge in human beings. J Allergy Clin Immunol 1996; 97: 646–54

    Article  PubMed  CAS  Google Scholar 

  39. Morelli JG, Yohn JJ, Lyons MB, et al. Leukotrienes C4 and D4 as potent mitogens for cultured human neonatal melanocytes. J Invest Dermatol 1989; 93: 719–22

    Article  PubMed  CAS  Google Scholar 

  40. Shaw RJ, Walsh GM, Cromwell O, et al. Activated human eosinophils generate SRS-A leukotrienes for IgG-dependent stimulation. Nature 1985; 316: 150–2

    Article  PubMed  CAS  Google Scholar 

  41. Weller PF, Lee CW, Foster DW, et al. Generation and metabolism of 5-lipoxygenase pathway leukotrienes in human eosinophils: predominant production of leukotriene C4. Proc Natl Acad Sci U S A 1983; 80: 7626–30

    Article  PubMed  CAS  Google Scholar 

  42. Lynch KR, O’Neill GP, Liu Q, et al. Characterization of the human cysteinyl leukotriene CysLT1 receptor. Nature 1999; 399: 789–93

    Article  PubMed  CAS  Google Scholar 

  43. Dahlen B, Zetterstrom O, Bjorck T, et al. The leukotriene-antagonist ICI-204,219 inhibits the early airway reaction to cumulative bronchial challenge with allergen in atopic asthmatics. Eur Respir J 1994; 7: 324–31

    Article  PubMed  CAS  Google Scholar 

  44. Leung DY, Soter NA. Cellular and immunologic mechanisms in atopic dermatitis. J Am Acad Dermatol 2001; 44: Sl–12

    Article  Google Scholar 

  45. Ikai K, Imamura S. Role of eicosanoids in the pathogenesis of atopic dermatitis. Prostaglandins Leukot Essent Fatty Acids 1993; 48: 409–16

    Article  PubMed  CAS  Google Scholar 

  46. Neuber K, Hilger RA, Konig W. Interleukin-3, interleukin-8, FMLP and C5a enhance the release of leukotrienes from neutrophils of patients with atopic dermatitis. Immunology 1991; 73: 83–7

    PubMed  CAS  Google Scholar 

  47. Shimizu T, Kristjansson S, Wennergren G, et al. Leukotriene B4 and C4 generation by blood leukocytes after ex vivo stimulation by Ca-ionophore and opsonized zymosan in children with atopic dermatitis. Pediatr Allergy Immunol 1994; 5: 95–9

    Article  PubMed  CAS  Google Scholar 

  48. Ruzicka T, Ring J. Enhanced releasability of prostaglandin E2 and leukotrienes B4 and C4 from leukocytes of patients with atopic eczema. Acta Derm Venereol 1987; 67(6): 469–75

    PubMed  CAS  Google Scholar 

  49. Fauler J, Neumann C, Tsikas D, et al. Enhanced synthesis of cysteinyl leukotrienes in atopic dermatitis. Br J Dermatol 1993; 128: 627–30

    Article  PubMed  CAS  Google Scholar 

  50. Sansom JE, Taylor GW, Dollery CT, et al. Urinary leukotriene E4 levels in patients with atopic dermatitis. Br J Dermatol 1997; 136: 790–1

    Article  PubMed  CAS  Google Scholar 

  51. Fogh K, Herlin T, Kragballe K. Eicosanoids in skin of patients with atopic dermatitis: prostaglandin E2 and leukotriene B4 are present in biologically active concentrations. J Allergy Clin Immunol 1989; 83: 450–5

    Article  PubMed  CAS  Google Scholar 

  52. Thorsen S, Fogh K, Broby-Johansen U, et al. Leukotriene B4 in atopic dermatitis: increased skin levels and altered sensitivity of peripheral blood T-cells. Allergy 1990; 45: 457–63

    Article  PubMed  CAS  Google Scholar 

  53. Meier F, Gross E, Klotz KN, et al. Leukotriene B4 receptors on neutrophils in patients with psoriasis and atopic eczema. Skin Pharmacol 1989; 2: 61–7

    Article  PubMed  CAS  Google Scholar 

  54. Chari S, Clark-Loeser L, Shupack J, et al. A role for leukotriene antagonists in atopic dermatitis? Am J Clin Dermatol 2001; 2: 1–6

    Article  PubMed  CAS  Google Scholar 

  55. Ortonne JP. Recent developments in the understanding of the pathogenesis of psoriasis. Br J Dermatol 1999; 140: 1–7

    Article  PubMed  CAS  Google Scholar 

  56. Brain S, Camp R, Dowd P, et al. The release of leukotriene B4-like material in biologically active amounts from the lesional skin of patients with psoriasis. J Invest Dermatol 1984; 83: 70–3

    Article  PubMed  CAS  Google Scholar 

  57. Schröder JM. Inflammatory mediators and chemoattractants. Clin Dermatol 1995; 13: 137–50

    Article  PubMed  Google Scholar 

  58. Camp R, Jones RR, Brain S, et al. Production of intraepidermal microabscesses by topical application of leukotriene B4. J Invest Dermatol 1984; 82: 202–4

    Article  PubMed  CAS  Google Scholar 

  59. De Jong EM, van Erp PEJ, van Vlijmen IMJ, et al. The interrelation between inflammation and epidermal proliferation in normal skin following epicutaneous application of leukotriene-B4 — an immunohistochemical study. Clin Exp Dermatol 1992; 17: 413–20

    Article  PubMed  Google Scholar 

  60. Ford-Hutchinson AW, Rackman A. Leukotrienes as mediators of skin inflammation. Br J Dermatol 1983; 109: 26–9

    Article  PubMed  CAS  Google Scholar 

  61. Fauler J, Neumann C, Tsikas D, et al. Enhanced synthesis of cysteinyl leukotrienes in psoriasis. J Invest Dermatol 1992; 99: 8–11

    Article  PubMed  CAS  Google Scholar 

  62. Izaki S, Yamamoto T, Goto Y, et al. Platelet-activating factor and arachidonic acid metabolites in psoriatic inflammation. Br J Dermatol 1996; 134: 1060–4

    Article  PubMed  CAS  Google Scholar 

  63. Kawana S, Nishiyama S. Pustular psoriasis and aseptic purulent arthritis: possible role of leukotrienes B4 and C4 in a flare of synovitis. Dermatology 1995; 190: 35–8

    Article  PubMed  CAS  Google Scholar 

  64. Stuning M, Schultz-Ehrenburg U, Altmeyer P, et al. Metabolism of [su14C]arachidonic acid by polymorphonuclear leukocytes in patients with psoriasis. Br J Dermatol 1987; 116: 153–9

    Article  PubMed  CAS  Google Scholar 

  65. Iversen L, Deleuran B, Hoberg AM, et al. LTA4 hydrolase in human skin: decreased activity but normal concentration in lesional psoriatic skin. Arch Dermatol Res 1996; 288: 217–24

    Article  PubMed  CAS  Google Scholar 

  66. Wedi B, Wagner S, Werfel T, et al. Prevalence of Helicobacter pylori associated gastritis in chronic urticaria. Int Arch Allergy Immunol 1998; 116: 288–94

    Article  PubMed  CAS  Google Scholar 

  67. Greaves MW, O’Donnell BF. Not all chronic urticaria is ‘idiopathic’! Exp Dermatol 1998; 7: 11–3

    CAS  Google Scholar 

  68. Juhlin L, Hammarstrom S. Wheal reactions in human skin after injection of leukotrienes B4, C4, D4 and E4. Prostaglandins Leukot Med l983; 11: 381–3

    Article  Google Scholar 

  69. Maltby NH, Ind PW, Causon RC, et al. Leukotriene E4 release in cold urticaria. Clin Exp Allergy 1989; 19: 33–6

    Article  PubMed  CAS  Google Scholar 

  70. Wedi B, Kapp A. Aspirin-induced adverse skin reactions: New pathophysiological aspects. Thorax 2000; 55: S70–1

    Article  PubMed  Google Scholar 

  71. Czech W, Schöpf E, Kapp A. Release of sulfidoleukotrienes in vitro: its relevance in the diagnosis of pseudoallergy to acetylsalicylic acid. Inflamm Res 1995; 44: 291–5

    Article  PubMed  CAS  Google Scholar 

  72. Szczeklik A. Mechanism of aspirin-induced asthma. Allergy 1997; 52: 613–9

    Article  PubMed  CAS  Google Scholar 

  73. Christie PE, Tagari P, Ford-Hutchinson AW, et al. Urinary leukotriene E4 concentrations increase after aspirin challenge in aspirin-sensitive asthmatic subjects. Am Rev Respir Dis 1991; 143: 1025–9

    PubMed  CAS  Google Scholar 

  74. Cowburn AS, Sladek K, Soja J, et al. Overexpression of leukotriene C4 synthase in bronchial biopsies from patients with aspirin-intolerant asthma. J Clin Invest 1996; 101: 1–13

    Google Scholar 

  75. Schmid M, Gode U, Schafer D, et al. Arachidonic acid metabolism in nasal tissue and peripheral blood cells in aspirin intolerant asthmatics. Acta Otolaryngol 1999; 119(2): 277–80

    Article  PubMed  CAS  Google Scholar 

  76. Szczeklik A, Sanak M. Genetic mechanisms in aspirin-induced asthma. Am J Respir Crit Care Med 2000; 161: S142–6

    PubMed  CAS  Google Scholar 

  77. Kawana S, Ueno A, Nishiyama S. Increased levels of immuno-reactive leukotriene B4 in blister fluids of bullous pemphigoid patients and effects of a selective 5-lipoxygenase inhibitor on experimental skin lesions. Acta Derm Venereol 1990; 70: 281–5

    PubMed  CAS  Google Scholar 

  78. Hackshaw KV, Voelkel NF, Thomas RB, et al. Urine leukotriene E4 levels are elevated in patients with active systemic lupus erythematosus. J Rheumatol 1992; 19: 252–8

    PubMed  CAS  Google Scholar 

  79. Lau CS, O’Dowd A, Belch JJ. White blood cell activation in Raynaud’s phenomenon of systemic sclerosis and vibration induced white finger syndrome. Ann Rheum Dis 1992; 51: 249–52

    Article  PubMed  CAS  Google Scholar 

  80. Willemsen MA, de Jong JG, van Domburg PH, et al. Defective inactivation of leukotriene B4 in patients with Sjogren-Larsson syndrome. J Pediatr 2000; 136: 258–60

    Article  PubMed  CAS  Google Scholar 

  81. Hamasaki Y, Miyazaki S. Leukotriene B4 and Kawasaki disease. Acta Paediatr Jpn 1991; 33: 771–7

    Article  PubMed  CAS  Google Scholar 

  82. Mayatepek E, Lehmann WD. Increased generation of cysteinyl leukotrienes in Kawasaki disease. Arch Dis Child 1995; 72: 526–7

    Article  PubMed  CAS  Google Scholar 

  83. Newburger JW, Burns JC. Kawasaki disease. Vasc Med 1999; 4: 187–202

    PubMed  CAS  Google Scholar 

  84. Kaler SG. Metabolic and molecular bases of Menkes disease and occipital horn syndrome. Pediatr Dev Pathol 1998; 1: 85–98

    Article  PubMed  CAS  Google Scholar 

  85. Kodama H, Murata Y. Molecular genetics and pathophysiology of Menkes disease. Pediatr Int 1999; 41: 430–5

    Article  PubMed  CAS  Google Scholar 

  86. Wenzel SE, Kamada AK. Zileuton: the first 5-lipoxygenase inhibitor for the treatment of asthma. Ann Pharmacother 1996; 30: 858–64

    PubMed  CAS  Google Scholar 

  87. Zhu YI, Stiller MJ. Preview of potential therapeutic applications of leukotriene B4 inhibitors in dermatology. Skin Pharmacol Appl Skin Physiol 2000; 13: 235–45

    Article  PubMed  CAS  Google Scholar 

  88. Tsuji F, Miyake Y, Enomoto H, et al. Effects of SA6541, a leukotriene A4 hydrolase inhibitor, and indomethacin on carrageenan-induced murine dermatitis. Eur J Pharmacol 1998; 346: 81–5

    Article  PubMed  CAS  Google Scholar 

  89. Kristensen M, Jinquan T, Thomsen MK, et al. ETH615, a synthetic inhibitor of leukotriene biosynthesis and function, also inhibits the production of and biological responses towards interleukin-8. Exp Dermatol 1993; 2: 165–70

    Article  PubMed  CAS  Google Scholar 

  90. Van Pelt JP, De Jong EM, Scijer MM, et al. Investigation of a novel and specific leukotriene B4 receptor antagonist in the treatment of stable plaque psoriasis. Br J Dermatol 1998; 139: 396–402

    Article  PubMed  Google Scholar 

  91. Seegers BA, Andriessen MP, van Hooijkonk CA, et al. Pharmacological effects of a specific leukotriene B(4) receptor antagonist (VML 295) on blood leukocytes, cutaneous inflammation and epidermal proliferation. Skin Pharmacol Appl Skin Physiol 2000; 13: 75–85

    Article  PubMed  CAS  Google Scholar 

  92. Marder P, Sawyer JS, Froelich LL, et al. Blockade of human neutrophil activation by 2-[2-propyl-3-3-2-ethyl-4-(4-fluorophenyl)-5-hydroxyphenoxy]propoxy]phenoxy]benzo ic acid (LY 293111), a novel leukotriene B4 receptor antagonist. Biochem Pharmacol 1995; 49: 1683–90

    Article  PubMed  CAS  Google Scholar 

  93. Simons FER, Johnston L, Gu X, et al. Suppression of the early and late cutaneous allergic responses using fexofenadine and montelukast. Ann Allergy Asthma Immunol 2001; 86: 44–50

    Article  PubMed  CAS  Google Scholar 

  94. Woodmansee DP, Simon RA. A pilot study examining the role of zileuton in atopic dermatitis. Ann Allergy Asthma Immunol 1999; 83: 548–52

    Article  PubMed  CAS  Google Scholar 

  95. Carucci JA, Washenik K, Weinstein A, et al. The leukotriene antagonist zafirlukast as a therapeutic agent for atopic dermatitis. Arch Dermatol 1998; 134: 785–6

    Article  PubMed  CAS  Google Scholar 

  96. De Jong EM, van Vlijmen IM, Scholte JC, et al. Clinical and biochemical effects of an oral leukotriene biosynthesis inhibitor (MK886) in psoriasis. Skin Pharmacol 1991; 4: 278–85

    Article  PubMed  Google Scholar 

  97. Degreef H, Dockx P, De Doncker P, et al. A double-blind vehicle-controlled study of R 68 151 in psoriasis: a topical 5-lipoxygenase inhibitor. J Am Acad Dermatol 1990; 22: 751–5

    Article  PubMed  CAS  Google Scholar 

  98. van de Kerkhof PC, Van Pelt H, Lucker GP, et al. Topical R-85355, a potent and selective 5-lipoxygenase inhibitor, fails to improve psoriasis. Skin Pharmacol 1996; 9: 307–11

    Article  PubMed  Google Scholar 

  99. Mommers JM, Van Rossum MM, Kooijmans-Otero ME, et al. VML 295 (LY-293111), a novel LTB4 antagonist, is not effective in the prevention of relapse in psoriasis. Br J Dermatol 2000; 142: 259–66

    Article  PubMed  CAS  Google Scholar 

  100. Ellis MH. Successful treatment of chronic urticaria with leukotriene antagonists. J Allergy Clin Immunol 1998; 102: 876–7

    Article  PubMed  CAS  Google Scholar 

  101. Spector S, Tan RA. Antileukotrienes in chronic urticaria [letter]. J Allergy Clin Immunol 1998; 101: 572

    Article  PubMed  CAS  Google Scholar 

  102. Berkun Y, Shalit M. Successful treatment of delayed pressure urticaria with montelukast. Allergy 2000; 55(2): 203–4

    Article  PubMed  CAS  Google Scholar 

  103. Hani N, Hartmann K, Casper C, et al. Improvement of cold urticaria by treatment with the leukotriene receptor antagonist montelukast [letter]. Acta Derm Venereol 2000; 80: 229

    Article  PubMed  CAS  Google Scholar 

  104. Asero R. Leukotriene receptor antagonists may prevent NSAID-induced exacerbations in patients with chronic urticaria. Ann Allergy Asthma Immunol 2000; 85: 156–7

    Article  PubMed  CAS  Google Scholar 

  105. Ohnishi-Inoue Y, Mitsuya K, Horio T. Aspirin-sensitive urticaria: provocation with a leukotriene receptor antagonist. Br J Dermatol 1998; 138: 483–5

    Article  PubMed  CAS  Google Scholar 

  106. Yanase DJ, David-Bajar KM. The leukotriene antagonist montelukast as a therapeutic agent for atopic dermatitis [abstract]. 58th Annual Meeting of the American Academy of Dermatology; 2000 Mar 10–15; San Francisco, CA. American Academy of Dermatology, 2000

  107. MacDowell-Carneiro AL, Hassan MH, Cotronei-Cascardo C, et al. Use of a leukotriene inhibitor in the treatment of chronic urticaria [abstract no. P117]. Ann Allergy Asthma Immunol 1999; 82: 113

    Google Scholar 

  108. Norris JG, Sullivan TJ. Leukotrienes and cytokines in steroid-dependent chronic urticaria [abstract no. P138]. Ann Allergy Asthma Immunol 1998; 80: 134

    Google Scholar 

  109. Chiu TJ, Warren MS. Zafirlukast (Accolate) in the treatment of chronic idiopathic urticaria 3 a case series [abstract]. J Allergy Clin Immunol 1998; 101 (Suppl.): S155

    Google Scholar 

  110. Asero R, Lorini M, Tedeschi A. Chronic unremitting urticaria: which patients respond to leukotriene receptor antagonists? [abstract no. 93]. Allergy 2001; 56Suppl. 68: 32

    Google Scholar 

  111. Reimers AR, Pichler C, Helblig A, et al. Treatment of chronic urticaria with zafirlukast. A double-blind, placebo-controlled cross-over study on 46 patients [abstract no. 455]. Allergy 2001; 56Suppl. 68: 149

    Google Scholar 

  112. Willemsen MA, Rotteveel JJ, Steijlen PM, et al. 5-lipoxygenase inhibition: a new treatment strategy for Sjogren-Larsson syndrome. Neuropediatrics 2000; 31: 1–3

    Article  PubMed  CAS  Google Scholar 

  113. Bjorneboe A, Smith AK, Bjorneboe GEA, et al. Effect of dietary supplementation with eicosapentaenoic acid in the treatment of atopic dermatitis. Br J Dermatol 1987; 118: 77–83

    Article  Google Scholar 

  114. MacDowell-Carneiro AL, Hurtado RC, Bellanti JA. Improvement of atopic eczema with a leukotriene inhibitor: a new therapeutic use? [abstract no. P78]. Ann Allergy Asthma Immunol 1998; 80: 119

    Google Scholar 

  115. Bensch G, Borish L. Leukotriene modifiers in chronic urticaria. Ann Allergy Asthma Immunol 1999; 83: 348

    Article  PubMed  CAS  Google Scholar 

  116. Israel E, Fischer AR, Rosenberg MA, et al. The pivotal role of 5-lipoxygenase products in the reaction of aspirin-sensitive asthmatics to aspirin. Am Rev Respir Dis 1993; 148: 1447–51

    Article  PubMed  CAS  Google Scholar 

  117. Leff JA, Busse WW, Pearlman D, et al. Montelukast, a leukotriene-receptor antagonist, for the treatment of mild asthma and exercise-induced bronchoconstriction. N Engl J Med 1998; 339: 147–52

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

The authors received no funding for the preparation of this manuscript and have no conflicts of interest with any relevant pharmaceutical companies.

Author information

Authors and Affiliations

  1. Department of Dermatology and Allergology, Hannover Medical University, Ricklinger Strasse 5, D-30449, Hannover, Germany

    Bettina Wedi & Alexander Kapp

Authors
  1. Bettina Wedi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Alexander Kapp
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Bettina Wedi.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Wedi, B., Kapp, A. Pathophysiological Role of Leukotrienes in Dermatological Diseases. BioDrugs 15, 729–743 (2001). https://doi.org/10.2165/00063030-200115110-00004

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00063030-200115110-00004

Keywords

Search

Navigation